Linomide is used as an immunomodulatory agent in research settings, particularly in studies related to autoimmune diseases and cancer. It has been investigated for its ability to stimulate the immune system by enhancing the activity of certain white blood cells, which may help the body fight tumor growth. It has also shown potential in delaying the onset of type 1 diabetes in preclinical models by altering immune responses that attack insulin-producing cells. Though not approved for routine clinical use, it remains a compound of interest in experimental immunology and therapeutic development.